Haemonetics Corporation (HAE)
US — Healthcare Sector
Automate Your Wheel Strategy on HAE
With Tiblio's Option Bot, you can configure your own wheel strategy including HAE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HAE
- Rev/Share 27.9019
- Book/Share 17.8435
- PB 3.6349
- Debt/Equity 1.4423
- CurrentRatio 1.6408
- ROIC 0.0855
- MktCap 3124776954.0
- FreeCF/Share 5.381
- PFCF 12.2023
- PE 18.3524
- Debt/Assets 0.5015
- DivYield 0
- ROE 0.1945
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HAE | Needham | Buy | Hold | -- | -- | Dec. 15, 2025 |
| Downgrade | HAE | Citigroup | Buy | Neutral | -- | $88 | Dec. 11, 2025 |
| Downgrade | HAE | Raymond James | Strong Buy | Outperform | -- | $78 | Aug. 11, 2025 |
| Downgrade | HAE | JP Morgan | Overweight | Neutral | -- | $62 | Aug. 8, 2025 |
| Reiterated | HAE | Barrington Research | -- | Outperform | $95 | $86 | Aug. 8, 2025 |
| Upgrade | HAE | Citigroup | Neutral | Buy | -- | $90 | July 9, 2025 |
| Initiation | HAE | Robert W. Baird | -- | Outperform | -- | $87 | June 26, 2025 |
| Downgrade | HAE | BofA Securities | Neutral | Underperform | $95 | $68 | Feb. 7, 2025 |
| Initiation | HAE | JP Morgan | -- | Overweight | -- | $116 | Dec. 6, 2024 |
| Initiation | HAE | CL King | -- | Buy | -- | $116 | Sept. 13, 2024 |
News
Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference
HAE
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
BOSTON , Feb. 24, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025 at 2:50 p.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://wsw.com/webcast/rj131/hae/1437678.
Read More
About Haemonetics Corporation (HAE)
- IPO Date 1991-05-10
- Website https://www.haemonetics.com
- Industry Medical - Instruments & Supplies
- CEO Christopher A. Simon
- Employees 3657
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.